Skip to main content

Advertisement

SpringerLink
Log in

Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Bladder cancer (BCa) is the seventh most common cancer among males worldwide. Some reliable markers in blood, urine, and tumor tissue, including clinicopathologic variables, molecular and inflammatory markers, gene polymorphisms, and tumor gene expression profiles are identified for predicting response to BCG immunotherapy in high-risk BCa patients.

Aims

We aimed to determine if FAS and FASL polymorphisms are associated with lack of response to BCG in patients with BCa.

Methods

The study included patients with primary non-muscle invasive BCa that had undergone transurethral resection (TUR). Patient demographics, BCa characteristics, use of BCG immunotherapy, lack of response to BCG (if administered), BCa recurrence, and fatty acid synthetase/fatty acid syntethase ligand (FAS/FASL) polymorphisms were investigated.

Results

The study included 127 patients with primary BCa. Mean age of the 107 (84.3%) male and 20 (15.7%) female patients was 59.3 ± 13.2 years. Among the patients that received BCG immunotherapy, more FAS homozygous patients had BCa recurrence than FAS polymorphism-negative patients (P < 0.001) and more patients with homozygote FASL polymorphisms had BCa recurrence than those with heterozygous FASL polymorphisms and no polymorphism.

Conclusion

Evaluation of FAS/FASL polymorphisms can predict lack of response to BCG immunotherapy and prevent the loss of valuable time before such alternative treatments as early cystectomy are initiated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041

    Article  PubMed  Google Scholar 

  2. Alfred Witjes J, Lebret T, Comperat E et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.eururo.2016.06.020

    Article  CAS  PubMed  Google Scholar 

  3. Zlotta A, Fleshner N, Jewett M (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3(6 Suppl 4):S199–S205

    PubMed  PubMed Central  Google Scholar 

  4. Zuiverloon T, Nieuweboer A, Vekony H, Kirkels W, Bangma C, Zwarthoff E (2012) Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61(1):128–145. https://doi.org/10.1016/j.eururo.2011.09.026

    Article  PubMed  Google Scholar 

  5. Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V (2015) Treatment of non-muscle invasive bladder cancer with bacillus Calmette-Guerin (BCG): biological markers and simulation studies. Bba Clin 4:27–34. https://doi.org/10.1016/j.bbacli.2015.06.002

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lima L, Ferreira J, Tavares A et al (2014) FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer. Urol Oncol 32(44):E41–E47

    Google Scholar 

  7. Lima L, Oliveira D, Ferreira J et al (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a southern Europe population. BJU Int 116(5):753–763. https://doi.org/10.1111/bju.12844

    Article  CAS  PubMed  Google Scholar 

  8. Moudi B, Salimi S, Farajian Mashhadi F, Sandoughi M, Zakeri Z (2013) Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. ScientificWorldJournal 2013:176741

    Article  Google Scholar 

  9. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A (2000) Perforin-mediated lysis of tumor cells by mycobacterium bovis bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6(9):3729–3738

    CAS  PubMed  Google Scholar 

  10. Zhang N, Jiang G, Liu X, Na R, Wang X, Xu J (2016) Prediction of bacillus Calmette-Guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies. Biomed Res Int 2016:9859021

    PubMed  PubMed Central  Google Scholar 

  11. Kang H, Tchey D, Yan C et al (2014) The predictive value of Gstt1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer. Urol Oncol 32(4):458–465. https://doi.org/10.1016/j.urolonc.2013.10.013

    Article  CAS  PubMed  Google Scholar 

  12. Ahirwar D, Agrahari A, Mandhani A, Mittal R (2009) Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14(4):213–218. https://doi.org/10.1080/13547500902818246

    Article  CAS  PubMed  Google Scholar 

  13. Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B (2006) Cytokine gene polymorphisms can alter the effect of bacillus Calmette-Guerin (Bcg) immunotherapy. Cytokine 35(1-2):1–5. https://doi.org/10.1016/j.cyto.2006.06.009

    Article  CAS  PubMed  Google Scholar 

  14. Gangwar R, Mandhani A, Mittal R (2010) Xpc gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. J Cancer Res Clin Oncol 136(5):779–786. https://doi.org/10.1007/s00432-009-0717-y

    Article  PubMed  Google Scholar 

  15. Mittal R, Singh R, Manchanda P et al (2008) Xrcc1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol Ther 7(5):645–650. https://doi.org/10.4161/cbt.7.5.5763

    Article  CAS  PubMed  Google Scholar 

  16. Houston A, O'connell J (2004) The FAS signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4(4):321–326. https://doi.org/10.1016/j.coph.2004.03.008

    Article  CAS  PubMed  Google Scholar 

  17. Reichmann E (2002) The biological role of the FAS/FASL system during tumor formation and progression. Semin Cancer Biol 12(4):309–315. https://doi.org/10.1016/S1044-579X(02)00017-2

    Article  CAS  PubMed  Google Scholar 

  18. Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, Zhang Z (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30(3):487–493. https://doi.org/10.1093/carcin/bgp016

    Article  CAS  PubMed  Google Scholar 

  19. Chopin D, Barei-Moniri R, Maille P et al (2003) Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 162(4):1139–1149. https://doi.org/10.1016/S0002-9440(10)63910-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Li C, Wu W, Liu J, Qian L, Li A, Yang K, Wei Q, Zhou J, Zhang Z (2006 Apr) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in South China: a case-control analysis. Pharmacogenet Genomics 16(4):245–251. https://doi.org/10.1097/01.fpc.0000194425.58511.a7

    Article  CAS  PubMed  Google Scholar 

  21. Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, Yaylim I, Ergen A, Ozturk O, Isbir T (2014 May-Jun) Functional genetic variants in apoptosis associated Fas and Fasl genes and risk of bladder cancer in a Turkish population. In Vivo 28(3):397–402

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yuksek Ihtisas Training and Research Hospital, Clinic of Urology, Health Sciences University, 06230, Ankara, Turkey

    Cavit Ceylan

  2. Yuksek Ihtisas Training and Research Hospital, Clinic of Urology, 06230, Ankara, Turkey

    Sedat Yahşi & Serkan Doğan

  3. Department of Medical Genetics, Ataturk Training and Research Hospital, 06800, Ankara, Turkey

    Elife ÖztÜrk

  4. Department of Medical Genetics, Ankara Yildirim Beyazit University, 06800, Ankara, Turkey

    Gulay Ceylan

Authors
  1. Cavit Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sedat Yahşi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serkan Doğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elife ÖztÜrk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gulay Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gulay Ceylan.

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no competing interests.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ceylan, C., Yahşi, S., Doğan, S. et al. Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer. Ir J Med Sci 187, 1115–1119 (2018). https://doi.org/10.1007/s11845-018-1764-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-018-1764-7

Keywords

Search

Navigation